The disclosure relates to a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The disclosure also relates to a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification. The disclosure further relates to a kit. The kit comprises a diketopiperazme, a prodrug of a diketopiperazme or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazme has the formula set forth in the specification.
